NDA 210589 · Fresenius Kabi USA
Omegaven
Fish Oil Triglycerides · Intravenous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 27, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
83
20 Phase 3, 3 recruiting
FAERS reports
91,003
44,188 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 5, 2025.
Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). Limitations of Use: • Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients [see Clinical Studies ( 14 )]. • It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6: omega-3 fatty acid ratio of the product [see Clinical Studies ( 14 )]. Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). ( 1 ) Limitations of Use: • Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients. ( 1 ) • It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product. ( 1 )
Mechanism: Omegaven provides a biologically utilizable source of calories and essential fatty acids. Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, as precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 27, 2018 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelOrphanLabelLetterReview
2 products under this application
- OMEGAVEN · FISH OIL TRIGLYCERIDES 10GM/100ML (0.1GM/ML) · EMULSION, INTRAVENOUS · Prescription
- OMEGAVEN · FISH OIL TRIGLYCERIDES 5GM/50ML (0.1GM/ML) · EMULSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fish Oil Triglycerides" as an intervention, any sponsor and status, largest first.
- The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal SurgeryPivotal-lookingCompleted
Jagiellonian UniversityAcademic, hospital or other
NCT00732849 · 600 participants · Start Jun 2002 · Primary completion Sep 2002
Drug: Reconvan, Dipeptiven, Omegaven · For: Gastrointestinal Surgery
Sites: Krakow, Poland
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery PatientsPivotal-lookingRecruiting
GCP-Service International West GmbHIndustry
NCT06279793 · 550 participants (planned) · Start Feb 15, 2024 · Primary completion Mar 2030
Drug: Fish Oil; Intravenous 0.9% Sodium Chloride · For: Intensive Care Unit; Coronary Artery Bypass Grafting (CABG); High Risk Patients and 9 more
Sites: Augsburg, Germany; Berlin, Germany; Bonn, Germany · 10 sites in all
- Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver CancerPivotal-lookingCompleted
Huazhong University of Science and TechnologyAcademic, hospital or other
NCT02321202 · 320 participants · Start Mar 2010 · Primary completion Sep 2013
Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition; Structolipid · For: Liver Cancer; Cirrhosis
Sites: Wuhan, China
- Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in InfantsCompleted
Baylor College of MedicineAcademic, hospital or other
NCT00738101 · 293 participants · Start Sep 2008 · Primary completion Mar 27, 2019
Drug: Omegaven · For: Cholestasis; Cholestasis of Parenteral Nutrition
Sites: Houston, Texas · 2 sites in all
- Effects of Omega-3 Fatty Acids on Outcome After Major Liver ResectionPivotal-lookingStatus unknown
University of ZurichAcademic, hospital or other
NCT01884948 · 258 participants (planned) · Start Jul 2013 · Primary completion Mar 2016
Drug: Omegaven™ · For: Major Liver Surgery
Sites: Zurich, Switzerland
- The Omega-3 Fatty Acid Paediatric Depression TrialPivotal-lookingCompleted
Gregor BergerAcademic, hospital or other
NCT03167307 · 257 participants · Start Apr 28, 2017 · Primary completion Mar 24, 2022
Drug: Omega 3 fatty acid; Placebo oil · For: Depression
Sites: Liestal, Switzerland; Zurich, Switzerland; Ganterschwil, Switzerland · 7 sites in all
- Efficacy and Safety of a Fish Oil Containing Lipid EmulsionPivotal-lookingCompleted
B. Braun Melsungen AGIndustry
NCT01176695 · 240 participants · Start Apr 2010 · Primary completion Apr 2011
Drug: fish oil containing lipid emulsion; MCT/LCT containing lipid emulsion · For: Parenteral Nutrition
Sites: Beijing, China; Nanjing, China
- Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer PatientsPivotal-lookingStatus unknown
Medical University of BialystokAcademic, hospital or other
NCT01704664 · 240 participants (planned) · Start Mar 2007 · Primary completion Jul 2021
Drug: glutamine; Perioperative parenteral immunonutrition (Dipeptiven, Omegaven) · For: Gastric Cancer
Sites: Bialystok, Poland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 221 |
| 2005 | 296 |
| 2006 | 331 |
| 2007 | 552 |
| 2008 | 1,128 |
| 2009 | 2,089 |
| 2010 | 3,308 |
| 2011 | 3,404 |
| 2012 | 4,433 |
| 2013 | 4,921 |
| 2014 | 5,081 |
| 2015 | 7,791 |
| 2016 | 8,130 |
| 2017 | 6,889 |
| 2018 | 6,407 |
| 2019 | 5,620 |
| 2020 | 5,184 |
| 2021 | 4,412 |
| 2022 | 4,751 |
| 2023 | 4,222 |
| 2024 | 4,434 |
| 2025 | 4,205 |
| 2026 | 3,193 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Parenteral fish oil-containing lipid emulsions may reverse parenteral nutrition-associated cholestasis in neonates: a systematic review and meta-analysis.
Park HW, Lee NM, Kim JH, et al. · J Nutr 2015 · Meta-Analysis, Systematic Review
- Parenteral fish oil as a pharmacological agent to modulate post-operative immune response: a randomized, double-blind, and controlled clinical trial in patients with gastrointestinal cancer.
de Miranda Torrinhas RS, Santana R, Garcia T, et al. · Clin Nutr 2013 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Safety and efficacy of n-3 fatty acid-based parenteral nutrition in patients with obstructive jaundice: a propensity-matched study.
Gong Q, Zhu P, Zhang B, et al. · Eur J Clin Nutr 2018 · Clinical Trial, Research Support, Non-U.S. Gov't
- ω-3 Fatty acids have no impact on serum lactate levels after major gastric cancer surgery.
Makay O, Kaya T, Firat O, et al. · JPEN J Parenter Enteral Nutr 2011 · Comparative Study, Randomized Controlled Trial
- Lipid emulsions for parenterally fed term and late preterm infants.
Kapoor V, Malviya MN, Soll R · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects.
Pluess TT, Hayoz D, Berger MM, et al. · Intensive Care Med 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.